Reviewer's report

Title: Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation

Version: 2 Date: 30 March 2006

Reviewer: John William W Stevens

Reviewer's report:

General

I accept the changes that have been made in response to my original comments.

-----------------------------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

-----------------------------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

-----------------------------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

-----------------------------------------------------------------------------------------------------------------

What next?: Accept without revision

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I hold shares in AstraZeneca and GlaxoSmithKline, which develop treatments for atrial fibrillation.